Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

By sjmartinez • November 23, 2023

Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer. 2023 Nov 11;186:107422. doi: 10.1016/j.lungcan.2023.107422. Epub ahead of print. PMID: 37992595.

Tags: durvalumab, health-related quality of life, Hematology/Oncology, Metastatic non-small-cell lung cancer, patient-reported outcomes, POSEIDON, Publications, tremelimumab

Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting

Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein[...]

Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium

Ho AS, Moyers JT, Attarian S, Banker R, Birkeland A, Chen MM, Coffey CS, Guo T, Haidar Y, Harris JP, Holsinger FC, Inman J, Jang[...]

Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Merryman RW, Rutherford SC, Ansell SM, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman JM, Zelenetz AD, Gutierrez M, Béguelin W, Casulo C, Cerhan[...]